Guangdong Taienkang Pharmaceutical Co., Ltd. was established in 1999. Its main business is agency operation, research and development, production and sales of pharmaceutical products, medical devices, sanitary materials, and provision of medical technology services and technology transfer. The main products are Heweizheng Intestine pills, "Woliten" lecithin complex iodine tablets and "Aitingjiu" dapoxetine hydrochloride tablets. The company aims to become an innovation-driven comprehensive pharmaceutical enterprise, relying on the stable cash flow generated by the agency operation business, and takes the independent research and development of drugs as a key measure to enhance its core competitiveness.

At the listing ceremony, Zheng Hanjie, chairman and general manager of Taienkang, Cai Rong, vice chairman of the Shantou CPPCC, Cai Xianghong, secretary of the Longhu District Committee of Shantou City, Mo Kailiang, first-level researcher of the Shantou Municipal Government, and deputy secretary of the Longhu District Committee of Shantou City Huang Xiaohuan, District Mayor, Lin Haihui, Party Secretary and Director of Shantou Financial Bureau, Liu Wenhua, Party Secretary of Shantou Federation of Industry and Commerce, Yang Fan, Managing Director of Guotai Junan Securities Investment Banking Department, and Sun Weiwen, Vice Chairman of Taienkang, jointly rang the listing bell. Leaders of the Shantou Municipal Government of Guangdong Province, leaders of the Shenzhen Stock Exchange, leaders of Guotai Junan Securities, shareholders of Taienkang, long-term partners, company management team, representatives of listing intermediaries and other guests from all walks of life witnessed this important moment. Through the cloud listing live broadcast hall, investors from all over the country and even the world gathered in the cloud to witness the bright moment of Taienkang’s listing on the ChiNext of Shenzhen Stock Exchange.

In the future, Taienkang will adhere to the strategy of endogenous growth, external expansion and integrated development, continue to deepen the pharmaceutical industry, and comprehensively improve the operating level. Through independent research and development and production of pharmaceutical products that meet market demand, enrich the company’s product structure, improve the core competitiveness of products, fully participate in market competition, and strive to become an innovative comprehensive pharmaceutical enterprise integrating "Research, Production and Sales".